Gastric cancer remains a major clinical challenge, as early symptoms are often nonspecific and many patients are diagnosed at an advanced stage, when prognosis is poor. Although PD-1 inhibitors ...
A cell and mouse study found that a PD-L1-targeted silver, doxorubicin and manganese dioxide nanosystem increased particle ...
How to Select First-Line Immunotherapy for Metastatic NSCLC: PD-L1, Disease Burden, and Co-Mutations
Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer. Selecting first-line ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Hosted on MSN
What is PD-L1, and why does it matter?
When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...
Researchers at the Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University have developed a way to observe how ...
The study showed OncoPrism-NSCLC significantly predicted overall response and identified the subset of patients with doubled median overall survival i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results